WallStreetZenWallStreetZen

NASDAQ: ACTU
Actuate Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for ACTU

Based on 2 analysts offering 12 month price targets for Actuate Therapeutics Inc

Min Forecast
$6.00+1,691.04%
Avg Forecast
$10.50+3,034.33%
Max Forecast
$15.00+4,377.61%

Should I buy or sell ACTU stock?

Based on 2 analysts offering ratings for Actuate Therapeutics Inc.

Strong Buy
Strong Buy
1 analysts 50%
Buy
1 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their ACTU stock forecasts and price targets.

ACTU stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-08-18
lockedlocked$00.00+00.00%2026-07-30

1 of 1

Forecast return on equity

Is ACTU forecast to generate an efficient return?

Company
-1,591.15%
Industry
21.29%
Market
171.95%
ACTU's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ACTU forecast to generate an efficient return on assets?

Company
-302.71%
Industry
21.83%
ACTU is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ACTU earnings per share forecast

What is ACTU's earnings per share in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
-$0.74
Avg 2 year Forecast
-$0.68
Avg 3 year Forecast
-$0.70

ACTU revenue forecast

What is ACTU's revenue in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

ACTU vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ACTU$0.34$10.50+3,034.33%Strong Buy
CURX$5.16N/AN/A
TPST$0.50$7.00+1,314.14%Buy
ENSC$0.42$2.00+375.06%Strong Buy
TOVX$0.17N/AN/A
View Top Biotech Stocks

Actuate Therapeutics Stock Forecast FAQ

Is Actuate Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: ACTU) stock is to Strong Buy ACTU stock.

Out of 2 analysts, 1 (50%) are recommending ACTU as a Strong Buy, 1 (50%) are recommending ACTU as a Buy, 0 (0%) are recommending ACTU as a Hold, 0 (0%) are recommending ACTU as a Sell, and 0 (0%) are recommending ACTU as a Strong Sell.

If you're new to stock investing, here's how to buy Actuate Therapeutics stock.

What is ACTU's earnings growth forecast for 2026-2028?

(NASDAQ: ACTU) Actuate Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.65%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.44%.

Actuate Therapeutics's earnings in 2026 is -$20,453,807.On average, 5 Wall Street analysts forecast ACTU's earnings for 2026 to be -$17,799,327, with the lowest ACTU earnings forecast at -$20,003,830, and the highest ACTU earnings forecast at -$15,381,096. On average, 5 Wall Street analysts forecast ACTU's earnings for 2027 to be -$16,248,009, with the lowest ACTU earnings forecast at -$19,297,813, and the highest ACTU earnings forecast at -$12,859,605.

In 2028, ACTU is forecast to generate -$16,901,195 in earnings, with the lowest earnings forecast at -$24,475,275 and the highest earnings forecast at -$12,607,456.

What is ACTU's revenue growth forecast for 2026-2028?

(NASDAQ: ACTU) Actuate Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 29.74%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.61%.

Actuate Therapeutics's revenue in 2026 is $0.On average, 5 Wall Street analysts forecast ACTU's revenue for 2026 to be $0, with the lowest ACTU revenue forecast at $0, and the highest ACTU revenue forecast at $0. On average, 5 Wall Street analysts forecast ACTU's revenue for 2027 to be $0, with the lowest ACTU revenue forecast at $0, and the highest ACTU revenue forecast at $0.

In 2028, ACTU is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is ACTU's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: ACTU) forecast ROA is -302.71%, which is lower than the forecast US Biotechnology industry average of 21.83%.

What is ACTU's Price Target?

According to 2 Wall Street analysts that have issued a 1 year ACTU price target, the average ACTU price target is $10.50, with the highest ACTU stock price forecast at $15.00 and the lowest ACTU stock price forecast at $6.00.

On average, Wall Street analysts predict that Actuate Therapeutics's share price could reach $10.50 by Aug 18, 2027. The average Actuate Therapeutics stock price prediction forecasts a potential upside of 3,034.33% from the current ACTU share price of $0.34.

What is ACTU's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: ACTU) Actuate Therapeutics's current Earnings Per Share (EPS) is -$0.87. On average, analysts forecast that ACTU's EPS will be -$0.74 for 2026, with the lowest EPS forecast at -$0.83, and the highest EPS forecast at -$0.64. On average, analysts forecast that ACTU's EPS will be -$0.68 for 2027, with the lowest EPS forecast at -$0.80, and the highest EPS forecast at -$0.54. In 2028, ACTU's EPS is forecast to hit -$0.70 (min: -$1.02, max: -$0.53).

What is ACTU's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: ACTU) forecast ROE is -1,591.15%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.